Shares of Cambridge’s Aegerion Pharmaceuticals Inc. rose after the company said that a European Union advisory panel recommended its drug be approved as a treatment for a rare inherited disease that causes high levels of bad cholesterol. Regulators are expected to make a decision in the third quarter. The pill, Lojuxta, is intended to be used along with a low-fat diet and other methods intended to reduce bad LDL cholesterol. US regulators approved the drug in December. Here, it is marketed under the name Juxtapid.